Tet1 and Tet2 maintain mesenchymal stem cell homeostasis via demethylation of the P2rX7 promoter

Ruili Yang1,2,3, Tingting Yu1,2, Xiaoxing Kou1,2, Xiang Gao2,4, Chider Chen2, Dawei Liu1,2, Yanheng Zhou1,3 & Songtao Shi2,3

Ten-eleven translocation (Tet) family-mediated DNA oxidation represents an epigenetic modification capable of converting 5-methylcytosine (5-mC) to 5-hydroxymethylcytosine (5-hmC), which regulates various biological processes. However, it is unknown whether Tet family affects mesenchymal stem cells (MSCs) or the skeletal system. Here we show that depletion of Tet1 and Tet2 results in impaired self-renewal and differentiation of bone marrow MSCs (BMMSCs) and a significant osteopenia phenotype. Tet1 and Tet2 deficiency reduces demethylation of the P2rX7 promoter and downregulates exosome release, leading to intracellular accumulation of miR-297a-5p, miR-297b-5p, and miR-297c-5p. These miRNAs inhibit Runx2 signaling to impair BMMSC function. We show that overexpression of P2rX7 rescues the impaired BMMSC function and bone homeostasis through demethylation of P2rX7 to control exosome and miRNA release. This Tet/P2rX7/Runx2 cascade may serve as a target for the development of novel therapies for osteopenia disorders.
The ten–eleven translocation (Tet) family is a group of DNA demethylases capable of regulating various epigenetic responses. Tet proteins, including Tet1, Tet2, and Tet3, are able to convert 5-methylcytosine (5-mC) to 5-hydroxymethylcytosine (5-hmC) and its oxidative derivatives in Fe(II)- and alpha-ketoglutarate (α-KG)-dependent oxidation reaction to promote DNA demethylation and gene transcription1–4. Previous studies showed that 5-hmC is abundant in both adult cells and embryonic stem cells (ESCs)5–7. Upon ESC differentiation, the expression levels of Tet1 and Tet2 are down-regulated, suggesting that Tet1 and Tet2 may be associated with the maintenance of ESC pluripotency through regulation of lineage-specific genes8. It was reported that the expressions of Tet1 and Tet2 were regulated by Oct4/Sox2 complex, and the depletion of Tet1 impairs the self-renewal and differentiation of ESCs5, 8. In contrast to its role in maintaining ESC pluripotency, Tet proteins have different effects on adult stem cells. Hematopoietic stem cells (HSCs) from Tet2-mutant mice exhibit increased repopulating capacity, augmented HSC expansion, and impaired differentiation toward the myeloid lineage9,10. Moreover, Tet2 and 5-hmC levels are increased during smooth muscle differentiation11. Adult Tet1-mutant mice exhibit defective self-renewal of neural progenitor cells and impaired memory extinction12. These studies suggest that Tet proteins may possess unique functional roles in epigenetic regulation of stem cell function. Depletion of Tet1 resulted in a reduction of 5-hmC levels and impaired chondrogenic differentiation in a chondrogenic progenitor cell line13. Additionally, 75% of the newborn Tet1-deletion mice exhibit a smaller body size at birth but seemed to gain their body weight when growing to 6–9 weeks14, suggesting a potential skeletal defect. However, the role of Tet proteins in skeletal development remains largely unknown.

Bone marrow mesenchymal stem cells (BMMSCs) are a population of non-hematopoietic multipotent stem cells with self-renewal and multipotent differentiation capacities. They play an essential role in maintaining bone/marrow homeostasis15, 16. BMMSCs can be regulated at both transcriptional and epigenetic levels in response to stimulation from various environmental elements17–19. BMMSC deficiency may contribute to bone degenerative phenotypes in osteopenia disease models20, 21.

In this study, we show that Tet1 and Tet2 are required to maintain BMMSC and bone homeostasis. The depletion of Tet1 and Tet2 may lead to hypermethylation of the Prx1 promoter to block miR-29a-5p, miR-29b-5p, and miR-29c-5p release, leading to downregulation of Runx2 signaling and osteopenia phenotype.

Results

BMMSCs express Tet proteins. Since Tet proteins are expressed in various tissues and play an essential biological role in epigenetic regulation, we hypothesized that Tet proteins may affect BMMSC function. We found that both human and mouse BMMSCs express Tet1, Tet2, and Tet3, as assessed by western blotting and real-time polymerase chain reaction (qPCR; Fig. 1a, b). Double immunostaining confirmed that BMMSCs co-express CD146, a mesenchymal stem cell marker, with Tet1, Tet2, and Tet3 (Fig. 1c). It was reported that different Tet proteins may display distinct roles in developmental processes9. To explore the possible roles of Tet family members in maintaining BMMSC and bone homeostasis, we used a BMMSC impairment model (ovariectomized (OVX) mice) to assess whether the expression levels of Tet family members were altered in impaired BMMSCs22. Micro-computed tomography (micro-CT) and histological analysis confirmed that bone mineral density (BMD), cortical bone area (Ct.Ar), cortical thickness (Ct.Th), and distal femoral trabecular bone volume of OVX mice were markedly decreased compared with the sham-treated group (Supplementary Fig. 1a–c). The number of colony-forming unit fibroblasts (CFU-F) was significantly elevated in OVX BMMSCs (Supplementary Fig. 1d). Bromodeoxyuridine (Brdu)-labeling assay confirmed that OVX BMMSCs had an increased proliferation rate (Supplementary Fig. 1e). Moreover, OVX BMMSCs showed impaired osteogenic differentiation, as indicated by reduced mineralized nodule formation assessed by alizarin red staining and reduced expression of the osteogenic genes runt-related transcription factor 2 (Runx2), alkaline phosphatase (ALP), and osteocalcin (OCN) after 14 days of osteogenic induction, assessed by western blotting (Supplementary Fig. 1f,g). Interestingly, we found that the expression levels of Tet1 and Tet2 were significantly decreased in OVX BMMSCs (Supplementary Fig. 1h). However, the Tet3 expression level remained unchanged. We detected a reduced level of 5-hmC in OVX mice bone marrow stem cells using immunostaining and dot blot assay (Supplementary Fig. 1i–j), consistent with the fact that Tet proteins convert 5-mC to 5-hmC.

Tet DKO mice show osteopenia phenotype and BMMSC impairment. To explore the role of Tet1 and Tet2 in maintaining BMMSC and bone homeostasis, we compared the bone phenotype of Prx1cre–/–, Tet1–/–, Prx1creTet2fl/fl, Tet1–/–, Prx1creTet2fl/fl double knockout (Tet DKO) mice at 8–10 weeks of age. Micro-CT and histological analysis showed that Tet DKO mice, but not in Tet1–/– mice, had significantly reduced BMD, bone volume/tissue volume (BV/TV), Ct.Ar, Ct.Th, and the distal femoral trabecular bone volume (Fig. 2a–c) compared to littermate controls (Fig. 2a–c). The BMD, BV/TV, Ct.Ar, and the distal femoral trabecular bone volume of Tet DKO mice were significantly lower than Tet1–/– and Prx1creTet2fl/fl mice, and the bone volume of Prx1creTet2fl/fl mice were lower than control group (Fig. 2a–c and Supplementary Fig. 2a). Then, we also performed a calcein-labeling assay to show that the Tet DKO mice had a lower bone turnover rate, which indicated that their bone formation rate was comparatively decreased (Fig. 2d).

To examine whether Tet1 and Tet2 affect BMMSC function, we isolated BMMSCs from 8–10-week-old Tet1–/–, Prx1creTet2fl/fl, Tet DKO mice and littermate controls (Supplementary Fig. 2a, b). Flow cytometric analysis showed that BMMSCs from both control and Tet DKO mice were positive for stem cell surface markers Sca1, PDGFR, CD105, CD90, and CD73, but were negative for hematopoietic lineage markers CD34 and CD45 (Supplementary Fig. 2c–d). The number of CFU-F was significantly elevated in Tet DKO but not Tet1–/– and Prx1creTet2fl/fl BMMSCs compared to the control group (Fig. 3a). BrdU-labeling assay confirmed that Tet DKO but not Tet1–/– and Prx1creTet2fl/fl BMMSCs had an increased proliferation rate (Fig. 3b). In addition, we found that Tet DKO and Prx1creTet2fl/fl BMMSCs but not Tet1–/– BMMSCs showed reduced osteogenic differentiation, as indicated by reduced mineralized nodule formation (Fig. 3c) and decreased expression levels of osteogenic-related genes Runx2, ALP, and OCN (Fig. 3d). In addition, the osteogenic differentiation capacity of Prx1creTet2fl/fl BMMSCs was significantly higher than Tet DKO BMMSCs (Fig. 3c, d). We further confirmed that BMMSCs derived from Tet DKO and Prx1creTet2fl/fl mice had significantly reduced capacity for new bone formation when subcutaneously implanted into immunocompromised mice (Fig. 3e). It was reported that Tet1 and Tet2 may compensate for each other24. Since the osteopenia phenotype of Tet DKO mice and the impairment of Tet DKO BMMSCs were significantly severe than that of Tet1–/– and Prx1creTet2fl/fl mice, we thus focus on study of Tet DKO mice. Control and Tet DKO BMMSCs showed similar adipogenic differentiation capacity under adipogenic induction, as
indicated by Oil Red O staining and the expression of adipogenic-related genes lipoprotein (LPL) and peroxisome proliferator-activated receptor γ2 (PPARγ2) (Supplementary Fig. 2d, e). These data indicate that Tet1 and Tet2 depletion impaired BMMSC function.

To further confirm the role of Tet1 and Tet2 in maintaining stem cell properties of BMMSCs in vitro, we used small interfering RNAs (siRNAs) to knockdown Tet1 and Tet2 expression in BMMSCs (Supplementary Fig. 2f). Knockdown of Tet1 and Tet2 in BMMSCs induced a higher proliferation rate (Supplementary Fig. 2g); reduced mineralized nodule formation (Supplementary Fig. 2h); decreased expression levels of osteogenic-related genes Runx2, ALP, and OCN (Supplementary Fig. 2i); and reduced capacity for new bone formation when subcutaneously implanted into immunocompromised mice (Supplementary Fig. 2j). The elevated proliferation rate and impairment of osteogenic differentiation were consistent with what was observed in Tet1- and Tet2-depleted BMMSCs. These data confirmed that Tet1 and Tet2 are required to maintain BMMSC stem cell properties.

miRNAs accumulate in Tet DKO. To explore the underlying molecular mechanisms, we performed RNA sequencing (RNA-seq) using RNA from control and Tet1/Tet2 siRNA-treated BMMSCs and found that around 80% of altered genes (p < 0.05 and fold change >2) were decreased in Tet1/Tet2 siRNA-treated BMMSCs compared to control group (Supplementary Fig. 3a).
Prx1 and littermates whose genetic status was distal femurs of control, Tet1−/−, Prx1creTet2fl/fl, and Tet DKO mice were analyzed by micro-CT. b The cortical bone area (Ct.Ar) and cortical thickness (Ct.Th) in the femur of control, Tet1−/−, Prx1creTet2fl/fl, and Tet DKO mice were assessed by micro-CT. c H&E staining showed the trabecular bone volume (yellow-circled area) in the distal femurs of control, Tet1−/−, Prx1creTet2fl/fl, and Tet DKO mice. d Calcein double labeling assay showed the bone formation rate in the metaphyseal trabecular bone of control and Tet DKO mice. The 8-10-week-old Tet1−/−Prx1creTet2fl/fl mice were used as Tet DKO mice in these experiments, and their littermates whose genetic status was Prx1creTet2fl/fl were used as controls. *p < 0.05, **p < 0.01, ***p < 0.001 (mean ± SD). Scale bars, 400 μm (a, b), 1 mm (c), and 25 μm (d). Results are from three independent experiments. p values were calculated using one-way ANOVA (a-c) and two-tailed Student’s t test (d).

Functional analysis using WebGestalt showed that 19 of the 40 most significant enriched phenotype categories were related to skeletal bone/cartilage development. These altered genes, including Runx2, ALP, Mmp2, Mx2, Sp7, and P2rX7, were highly related with abnormal skeleton development. Runx2 is one of the most significant altered genes in all of the 19-phenotype categories (Supplementary Fig. 3b and Supplementary Table 3). Since Tet DKO mice displayed a significant osteopenia phenotype and lower bone formation rate in vivo25, 26, we used western blotting and qPCR analysis to show reduced expression of Runx2 in Tet DKO BMSCs. (Fig. 4a, b). After 14-day osteogenic induction, the expression levels of Runx2, ALP, and OCN were decreased in Tet DKO BMSCs compared to control group (Fig. 3d). We compared the expression levels of Runx2, ALP, and OCN on different days after osteogenic induction to investigate if ALP and OCN were potential direct targets or downstream molecules of Runx2. The result showed that the expression level of Runx2, but not ALP and OCN, significantly decreased without osteogenic induction and under 3 days of induction (Supplementary Fig. 3c), suggesting that ALP and OCN may be the downstream target of Runx2. There were also less Runx2-positive cells in femur of Tet DKO mice compared to control ones (Supplementary Fig. 3d). Next, to evaluate if Runx2 can be a direct target for Tet1 and Tet2, we analyzed the Runx2 promoter using Methprimer software and
found Runx2 promoter lacks CpG island (Supplementary Fig. 3e). We next used chromatin immunoprecipitation (ChiP)-qPCR to analyze if Tet1/Tet2 could directly binding to the site where CpG was comparably rich in the Runx2 promoter, and the result showed that no binding site was detected (Supplementary Fig. 3f). Thus, we search potential molecules that may connect Tet with Runx2. Since osteogenic differentiation can be governed by microRNAs (miRNAs) via post-transcriptional regulation, we investigated whether the variation of miRNAs in Tet DKO BMMSCs contributed to the altered Runx2 expression. We used MicroCosm Targets software to identify 19 miRNAs that may target Runx2 gene expression (Supplementary Table 1). Interestingly, qPCR analysis showed that the levels of miR-297a-5p, miR-297b-5p, and miR-297c-5p in Tet DKO BMMSCs were significantly higher than in control BMMSCs (Fig. 4c). To further evaluate the functional role of miR-297a-5p, miR-297b-5p, and miR-297c-5p, we used mimics of these miRNAs to treat BMMSCs and inhibitors of these miRNAs to treat Tet DKO BMMSCs (Supplementary Fig. 3g, h). Tet DKO BMMSCs treated with these miRNA inhibitors showed elevated mineralized nodule formation (Fig. 4d, e) and increased expression levels of Runx2, ALP, and OCN under 14 days of osteogenic induction (Fig. 4f and Supplementary Fig. 3i). Moreover, under osteo-inductive conditions, BMMSCs treated with miR-297a-5p, miR-297b-5p, or miR-297c-5p mimics showed reduced mineralized nodule formation (Fig. 4g) and decreased expression levels of osteogenic-related...
genes Runx2, ALP, and OCN (Fig. 4h, i and Supplementary Fig. 3j). The proliferation rate of Tet DKO BMSCs was decreased by the miR-297b-5p or miR-297c-5p inhibitor treatment (Supplementary Fig. 3k), while the proliferation rate was significantly upregulated in BMSCs treated with miR-297b-5p or miR-297c-5p mimics (Supplementary Fig. 3l). Collectively, these data indicate that the accumulation of miR-297a-5p, miR-297b-5p, and miR-297c-5p in Tet DKO BMSCs blocks Runx2 signaling and results in impaired osteogenic differentiation and elevated proliferation.

**Tet1 and Tet2 control exosome/miRNA secretion in BMSCs.**
Next, we examined how miR-297a-5p, miR-297b-5p, and miR-297c-5p accumulated in Tet DKO BMSCs. We could not detect CpG island on the promoter of these three miRNAs, indicating
that these may not be directly targeted by Tet1 and Tet2. MSCs can secrete a large number of exosomes\textsuperscript{32}, which can transfer proteins, mRNAs, and miRNAs to mediate physiological and pathological processes\textsuperscript{19, 33, 34}. We therefore sought to test whether exosome secretion is involved in miRNA accumulation in Tet DKO BMMSCs. We found that the amount of exosome-like extracellular vesicles in Tet DKO BMMSCs was significantly decreased when compared to the control BMMSCs, as quantified using a Bradford assay (Fig. 5a). We verified that the extracellular vesicles identified in this assay were indeed exosomes, as they

![Exosome protein per 1 x 10^6 cells (μg)](image)

**Exosome protein per 1 x 10^6 cells (μg)**

|       | Control | Tet DKO |
|-------|---------|---------|
| Exosome protein (μg) | 3 ± 0.5 | 2 ± 0.2 |

![Exosome number x 10^8 per 1 x 10^6 cells](image)

**Exosome number x 10^8 per 1 x 10^6 cells**

|       | Control | Tet DKO |
|-------|---------|---------|
| Exosome number x 10^8 | 25 ± 2 | 10 ± 1 |

![Exosome protein per 1 x 10^6 cells (μg)](image)

**Exosome protein per 1 x 10^6 cells (μg)**

|       | Control | Tet DKO |
|-------|---------|---------|
| Exosome protein (μg) | 3 ± 0.5 | 2 ± 0.2 |

![Exosome number x 10^8 per 1 x 10^6 cells](image)

**Exosome number x 10^8 per 1 x 10^6 cells**

|       | Control | Tet DKO |
|-------|---------|---------|
| Exosome number x 10^8 | 25 ± 2 | 10 ± 1 |

![Exosome protein per 1 x 10^6 cells (μg)](image)

**Exosome protein per 1 x 10^6 cells (μg)**

|       | Control | Tet DKO |
|-------|---------|---------|
| Exosome protein (μg) | 3 ± 0.5 | 2 ± 0.2 |

![Exosome number x 10^8 per 1 x 10^6 cells](image)

**Exosome number x 10^8 per 1 x 10^6 cells**

|       | Control | Tet DKO |
|-------|---------|---------|
| Exosome number x 10^8 | 25 ± 2 | 10 ± 1 |

![Exosome protein per 1 x 10^6 cells (μg)](image)

**Exosome protein per 1 x 10^6 cells (μg)**

|       | Control | Tet DKO |
|-------|---------|---------|
| Exosome protein (μg) | 3 ± 0.5 | 2 ± 0.2 |

![Exosome number x 10^8 per 1 x 10^6 cells](image)

**Exosome number x 10^8 per 1 x 10^6 cells**

|       | Control | Tet DKO |
|-------|---------|---------|
| Exosome number x 10^8 | 25 ± 2 | 10 ± 1 |

![Exosome protein per 1 x 10^6 cells (μg)](image)

**Exosome protein per 1 x 10^6 cells (μg)**

|       | Control | Tet DKO |
|-------|---------|---------|
| Exosome protein (μg) | 3 ± 0.5 | 2 ± 0.2 |

![Exosome number x 10^8 per 1 x 10^6 cells](image)

**Exosome number x 10^8 per 1 x 10^6 cells**

|       | Control | Tet DKO |
|-------|---------|---------|
| Exosome number x 10^8 | 25 ± 2 | 10 ± 1 |

![Exosome protein per 1 x 10^6 cells (μg)](image)

**Exosome protein per 1 x 10^6 cells (μg)**

|       | Control | Tet DKO |
|-------|---------|---------|
| Exosome protein (μg) | 3 ± 0.5 | 2 ± 0.2 |

![Exosome number x 10^8 per 1 x 10^6 cells](image)

**Exosome number x 10^8 per 1 x 10^6 cells**

|       | Control | Tet DKO |
|-------|---------|---------|
| Exosome number x 10^8 | 25 ± 2 | 10 ± 1 |

![Exosome protein per 1 x 10^6 cells (μg)](image)

**Exosome protein per 1 x 10^6 cells (μg)**

|       | Control | Tet DKO |
|-------|---------|---------|
| Exosome protein (μg) | 3 ± 0.5 | 2 ± 0.2 |

![Exosome number x 10^8 per 1 x 10^6 cells](image)

**Exosome number x 10^8 per 1 x 10^6 cells**

|       | Control | Tet DKO |
|-------|---------|---------|
| Exosome number x 10^8 | 25 ± 2 | 10 ± 1 |

![Exosome protein per 1 x 10^6 cells (μg)](image)

**Exosome protein per 1 x 10^6 cells (μg)**

|       | Control | Tet DKO |
|-------|---------|---------|
| Exosome protein (μg) | 3 ± 0.5 | 2 ± 0.2 |

![Exosome number x 10^8 per 1 x 10^6 cells](image)

**Exosome number x 10^8 per 1 x 10^6 cells**

|       | Control | Tet DKO |
|-------|---------|---------|
| Exosome number x 10^8 | 25 ± 2 | 10 ± 1 |

![Exosome protein per 1 x 10^6 cells (μg)](image)

**Exosome protein per 1 x 10^6 cells (μg)**

|       | Control | Tet DKO |
|-------|---------|---------|
| Exosome protein (μg) | 3 ± 0.5 | 2 ± 0.2 |

![Exosome number x 10^8 per 1 x 10^6 cells](image)

**Exosome number x 10^8 per 1 x 10^6 cells**

|       | Control | Tet DKO |
|-------|---------|---------|
| Exosome number x 10^8 | 25 ± 2 | 10 ± 1 |

![Exosome protein per 1 x 10^6 cells (μg)](image)

**Exosome protein per 1 x 10^6 cells (μg)**

|       | Control | Tet DKO |
|-------|---------|---------|
| Exosome protein (μg) | 3 ± 0.5 | 2 ± 0.2 |

![Exosome number x 10^8 per 1 x 10^6 cells](image)

**Exosome number x 10^8 per 1 x 10^6 cells**

|       | Control | Tet DKO |
|-------|---------|---------|
| Exosome number x 10^8 | 25 ± 2 | 10 ± 1 |
expressed exosome markers CD9 and CD81 (Fig. 5b). Exosomes derived from Tet DKO BMSCs expressed reduced levels of CD9 and CD81 compared to control BMSCs (Fig. 5b). Furthermore, we used an EXOCEP exosome quantitation kit to show that the exosome secretion was decreased in Tet DKO BMSCs (Fig. 5c)35. More intracellular exosomes accumulated in Tet DKO BMSCs compared to control BMSCs, as indicated by more CD9-positive and CD81-positive intracellular exosomes of Tet DKO BMSCs analyzed by immunofluorescence staining and more vesicle accumulation analyzed by transmission electron microscopy (Fig. 5d, e). Previous studies indicated that P2rX7 is capable of controlling exosome release36-38. Immunocytofluorescence staining showed the co-localization of P2rX7 with MHC surface molecule CD146, along with reduced expression level of P2rX7 in Tet DKO BMSCs (Fig. 5f). We showed that the expression level of P2rX7 was decreased in Tet DKO BMSCs compared to the control group (Fig. 5g, h). In addition, we discovered decreased P2rX7 expression levels in Tet1 and Tet2 siRNA-treated BMSCs (Supplementary Fig. 4a). Previous studies indicated that Tet1 and 5-hmC prefer to co-localize at transcriptional start sites of CpG-rich promoters27, 28. In order to investigate whether Tet1 and Tet2 directly regulate P2rX7, we used ChIP-qPCR analysis to show that Tet1 and Tet2 bind to the CpG island of P2rX7 promoter (Supplementary Fig. 4b, Fig. 5i, j). We next examined whether deletion of Tet1 and Tet2 affected the enrichment of 5-hmC level at the P2rX7 promoter. Hydroxymethylated DNA immunoprecipitation (hMeDIP)-qPCR analysis revealed that Tet DKO BMSCs showed a remarkably decreased 5-hmC level compared to control BMSCs (Fig. 5k). Consistently, Tet1 and Tet2 siRNA-treated BMSCs also displayed reduced 5-hmC enrichment at the P2rX7 promoter (Supplementary Fig. 4c). MeDIP-qPCR analysis revealed that Tet DKO BMSCs showed increased 5-mC level compared to control BMSCs (Supplementary Fig. 4d). OxBS sequencing analysis also showed that Tet DKO BMSCs displayed elevated methylation in the promoter of P2rX7 locus compared to control BMSCs (Supplementary Fig. 4e). These data suggest that P2rX7 is a direct target of Tet1 and Tet2 for DNA demethylation. Moreover, we detected the overall level of 5-hmC and 5-mC in BMSCs by dot blot assay and showed that the level of 5-hmC was lower in Tet DKO BMSCs than the control group, while the level of 5-mC was elevated in Tet DKO BMSCs (Supplementary Fig. 4f, g). Furthermore, we overexpressed wildtype Tet1 and Tet2 plasmid and catalytic domain inactive Tet1 and Tet2 plasmid on Tet- DKO BMSCs to analyze whether overexpression could rescue the decreased expression of P2rX7 and osteogenic differentiation. The results showed that wildtype Tet1 and Tet2 plasmid, but not catalytic domain inactive ones, overexpression rescued decreased expression of P2rX7 in Tet DKO BMSCs (Supplementary Fig. 4h). Wildtype, but not catalytic domain inactive, Tet1 and Tet2 plasmid overexpression also elevated the mineralized nodule formation and expression levels of Runx2, ALP, and OCN under osteogenic induction (Supplementary Fig. 4h-j).

To further verify the role of P2rX7 in BMSC differentiation, we used siRNA to knockdown P2rX7 expression in control BMSCs (Supplementary Fig. 4k). qPCR analysis showed that siP2rX7-treated BMSCs had increased levels of intracellular miR-297a-5p, miR-297b-5p, and miR-297c-5p (Fig. 5l). Furthermore, siP2rX7-treated BMSCs showed a reduced capacity to secrete exosomes into the culture supernatant (Fig. 5m), as well as decreased expression levels of exosome-associated proteins CD9 and CD81 compared to the control BMSCs (Fig. 5n). Under osteo-inductive conditions, siP2rX7-treated BMSCs showed reduced mineralized nodule formation (Fig. 5o) and decreased expression levels of osteogenic-related genes Runx2, ALP, and OCN (Fig. 5p). Taken together, these findings suggest that Tet1 and Tet2 are required to maintain BMSC exosome/miRNA secretion through regulating P2rX7 demethylation.

**P2rX7 activation rescues impairment of Tet DKO BMSCs.** Since P2rX7 deficiency in Tet DKO BMSCs led to the impairment of BMSC functions, we used a P2rX7 CRISPR activation plasmid to rescue the P2rX7 level in Tet DKO BMSCs in vitro (Supplementary Fig. 5a). Overexpression of P2rX7 facilitated the release of accumulated miR-297a-5p, miR-297b-5p, and miR-297c-5p from Tet DKO BMSCs (Fig. 6a) and improved exosome secretion (Fig. 6b). Western blotting showed the expression levels of CD9 and CD81 were also elevated (Fig. 6c). Moreover, osteogenic differentiation of P2rX7-overexpressing Tet DKO BMSCs was markedly improved compared to untreated Tet DKO BMSCs, as assessed by alizarin red staining to show elevated mineralized nodule formation (Fig. 6d) and western blotting to show increased expression of the osteogenic genes Runx2, ALP, and OCN (Fig. 6e). We overexpressed P2rX7 in BMSCs and subsequently implanted into immuno-compromised mice subcutaneously with hydroxyapatite/tricalcium phosphate (HA/TCP) as carrier. The result showed that P2rX7 overexpression elevated BMSC-mediated in vivo new bone formation (Supplementary Fig. 5b).

We next investigated the effect of overexpressing P2rX7 in 8-10-week-old Tet DKO mice by systemic injection of adenovirus-associated P2rX7 overexpression virus (P2rX7 AAV), P2rX7 AAV or control AAV were injected once a week for up to 4 weeks (Supplementary Fig. 5c). To analyze the efficiency of P2rX7 AAV treatment, we used immunostaining to show the increased P2rX7 expression in P2rX7 AAV-treated Tet DKO mouse bone marrow.
cells (Supplementary, Fig. 5d-f). P2rX7 AAV-treated Tet DKO BMMSCs were collected and found to have reduced intracellular levels of miR-297a-5p, miR-297b-5p, and miR-297c-5p (Fig. 6f), improved capacity to secrete exosomes into the culture supernatant (Fig. 6g), and elevated expression of CD9 and CD81 (Fig. 6h and Supplementary, Fig. 5g). Micro-CT and histological analysis showed that P2rX7 AAV-treated Tet DKO mice displayed significantly increased BMD, Ct.Ar, Ct.Th, and distal femoral trabecular bone volume compared to control AAV-treated Tet DKO mice (Fig. 6i-l). Under osteo-inductive conditions, the osteogenic differentiation of BMMSCs derived from P2rX7 AAV-treated Tet DKO mice showed marked

### Graphical Data

**Figure 6**

- **A**: Relative expression of miR-297a-5p, miR-297b-5p, and miR-297c-5p.
- **B**: Exosome protein per 1×10^6 cells (μg).
- **C**: Exosomes kD (CD9, CD81).
- **D**: Alizarin red-positive area/total area (%).
- **E**: Runx2, ALP, OCN, β-actin.
- **F**: Relative expression of miR-297a-5p, miR-297b-5p, and miR-297c-5p.
- **G**: Exosome protein per 1×10^6 cells (μg).
- **H**: Exosomes kD (CD9, CD81).
- **I**: Micro-CT and histological analysis of BMD (g/cm^3).
- **J**: Ct.Ar (mm^2).
- **K**: Ct.Th (mm).
- **L**: Trabecular bone/total area (%).
- **M**: Alizarin red-positive area/total area (%).
- **N**: Runx2, ALP, OCN, β-actin.

**Supplementary Figures**

- **Supplementary Fig. 5**: Additional data on miR-297 expression and exosome secretion.
- **Supplementary Fig. 6**: Detailed analysis of osteogenic differentiation under osteo-inductive conditions.
improvement when compared to control AAV-treated Tet DKO BMMSCs, as indicated by elevated mineralized nodule formation (Fig. 6m) and increased expression of the osteogenic genes Runx2, ALP, and OCN (Fig. 6n). The cell proliferation rate was decreased after the P2rX7 AAV treatment relative to Tet DKO BMMSCs, as assessed by BrdU-labeling assay (Supplementary, Fig. 5h). To verify the role of P2rX7 on bone formation, we used P2rX7 AAV to treat osteopenia (OVX) mice. Micro-CT and histological analysis showed that P2rX7-treated OVX mice had significantly increased BMD, Ct.Ar, Ct.Th, and the distal femoral trabecular bone volume when compared to OVX mice (Supplementary Fig. 6a, c). Moreover, P2rX7 AAV treatment could rescue decreased osteogenic differentiation capacity, but not the elevated proliferation rate in OVX BMMSCs (Supplementary Fig. 6d, f). Collectively, these data indicate that P2rX7 is capable of regulating intracellular levels of miR-297a-5p, miR-297b-5p, and miR-297c-5p through the control of exosome release. Elevating P2rX7 levels in Tet DKO mice rescued BMMSC function and osteopenia phenotype (Supplementary Fig. 7).

Discussion

The Tet family contributes to DNA demethylation and acts as a key regulator of epigenetic modulation1, 2, 3. In this study, we generated Tet1−/−;Ptx1−/−Tet2−/− (Tet DKO) conditional knockout mice to reveal the functional role of Tet1 and Tet2 in maintaining BMMSC properties and bone homeostasis. Previous studies showed that loss of Tet2 leads to increased replicating capacity in hematopoietic stem cell and myeloid transformation39, 40. Inhibition of Tet1/2 suppresses proliferation of umbilical cord (UC)-derived MSCs41 and Nanog expression in embryonic stem cells (ES)1. Here we showed that Tet1 and Tet2 depletion elevated the proliferation of BMMSCs. Previous study reported that MSCs derived from adipose tissue, BM, and UC origin showed differential pattern of IGF2BP1 expression41, implying that the different roles of Tet1/2 on stem cell proliferation may be regulated by IGF2BP1 or other molecules. Tet DKO BMMSCs exhibited a significant impairment in osteogenic differentiation, which contribute to the osteopenia phenotype observed on Tet DKO mice. It was reported that newborns of Tet1 and Tet2 conventional knockout mice did not show developmental delay although a fraction of these double knockout mice were smaller in size57, 58. Suggestively the osteopenia phenotype observed in Tet DKO mice may be attributed to the impairment of BMMSC osteogenic differentiation. Bone homeostasis is a tightly regulated process, balancing new bone formation by BMMSC-derived osteoblasts with bone resorption by osteoclasts. Signals that determine the recruitment, replication, apoptosis, and differentiation of cells of both lineages may increase osteopenia risk42, 43. For instance, alteration of histone H3K9 acetyltransferase PCAF (p300/CBP-associated factor)44, mammalian target of rapamycin (mTOR) signaling45 and hydrogen sulfide levels46 may lead to osteopenia by impairing osteogenic differentiation of BMMSCs. Our previous studies demonstrated that the depletion of Tet1 and Tet2 leads to impairment of regulatory T cell differentiation and immune system disorders47. Mutation of Tet2 in HSCs has been reported to impair their function and leads to diverse myeloid malignancies48. Except the direct effect of Tet on BMMSCs, whether immune disorder or abnormal of HSCs caused by Tet mutation contributed to bone disorders and BMMSCs impairment need to be further investigated49.

In this study, we proposed a mechanism by which Tet1 and Tet2 may function as upstream epigenetic regulators of P2rX7-controlled exosome release. Exosomes play an important role in intercellular communication because they are able to transfer proteins, mRNAs, and miRNAs50, contributing to a variety of physiologic processes, including cell homeostasis, differentiation, immune responses, and neuronal signaling51, 52. Aberrant exosome secretion may be associated with various human diseases, such as Parkinson’s disease, multiple sclerosis, and Alzheimer’s disease52–54. It is known that multiple microenvironment factors including inflammatory cytokines, hypoxia, and infectious agents are capable of promoting MSC secretion through the activation of an exocytotic pathway55. However, whether MSC exosome secretion is modulated by epigenetic modification has remained unclear. In this study, we showed that Tet1 and Tet2 directly bind to the CpG island of P2rX7 promoter to directly regulate its demethylation activity36–38. P2rX7 is an ionotropic receptor that is controlled by adenosine triphosphate. Activation of P2rX7 triggers a remarkably diverse range of membrane trafficking responses in leukocytes and epithelial cells56. The significance of P2rX7 in regulating bone development and homeostasis has been demonstrated by previous studies. Bone deficiency was observed in P2rX7 knockout mice57, 58. The combination of this evidence prompted us to further examine the functional role of P2rX7 in regulating MSC secretion and differentiation. In this study, we demonstrated that the activation of P2rX7 increased the amount of exosome secretion from Tet DKO BMMSCs. P2rX7 deficiency led to the impairment of osteogenic differentiation of BMMSCs. Collectively, our studies reveal that P2rX7 is a target of Tet demethylation, and that Tet1 and Tet2 can directly modulate P2rX7, thereby controlling BMMSC exosome release to maintain bone and BMMSC homeostasis. Tet1 and Tet2 deficiency also reduced the overall level of 5-hmC in BMMSCs, downregulating expression of other potential molecular targets. Further investigation is required to identify and characterise other downstream target molecules of Tet1 and Tet2 in BMMSCs.
The miRNAs are small non-coding RNAs with a length of 18–23 nucleotides that function as post-transcriptional regulators of gene expression. Herein, we computationally identified 19 miRNAs that may target Runx2. Tet DKO BMMSCs showed a different miRNA expression profile than that of control BMMSCs. Previous studies showed that miR-29b, miR-26a, and miR-767 can target Tet1 to inhibit its expression, leading to a change in 5-hmC levels.66,67 Conversely, the Tet family can also directly modulate miR-200 by demethylating the CpG islands of the miR-200 promoter.63 In this study, as there is no CpG island on the promoter of miR-297a-5p, miR-297b-5p, and miR-297c-5p, we reveal a mechanism of interaction between the Tet family and miRNAs and show that Tet1 and Tet2 depletion leads to P2rX7 promoter hypermethylation and reduced exosome secretion. This results in intracellular accumulation of miR-297a-5p, miR-297b-5p, and miR-297c-5p in Tet DKO BMMSCs. In turn, the intracellular accumulation of miR-297a-5p, miR-297b-5p, and miR-297c-5p decreases the osteogenic differentiation of Tet DKO BMMSCs by inhibiting Runx2 signaling. Interestingly, we also found that the proliferation rate of BMMSCs is elevated after miR-297b-5p and miR-297c-5p treatment, which is consistent with our findings on Tet DKO BMMSCs. Previous studies indicated that the biological role of Runx2 is not restricted to activating osteoblast lineage-specific genes; it also contributes to negative control of cell proliferation.64 Our finding may help to explain why the Runx2-deficient in Tet DKO BMMSCs and the intracellular accumulation of Runx2-targeting miRNAs results in the impairment of osteogenic differentiation and elevated proliferation rate. Overexpression of P2rX7 in Tet2-deficient mice rescues the exosome release and accumulation status of miR-297a-5p, miR-297b-5p, and miR-297c-5p in Tet DKO BMMSCs. In vivo overexpression of P2rX7 rescues the osteosarcoma phenotype and BMSC function in Tet DKO mice, suggesting that P2rX7 may be a potential therapeutic target for treating Tet-associated skeletal disorders. Based on the previous studies, deletion of Tet proteins might lead to other pathogenic process other than osteopenia.65 Thus, the effect of the exosome secretion impairment caused by Tet deletion might have a broad effect on miRNA release, which may not only specify to the miRNAs targeting Runx2. Global gene analysis showed Runx2 cluster genes were altered after Tet1 and Tet2 knockdown in BMMSCs, implying that the Tet/P2rX7/Runx2 cascade may be one of critical regulating mechanism to maintain bone homeostasis and BMSC function. As 5-hmC may be involved in establishing and maintaining chromatin structure for both actively transcribed genes and PcG-repressed regulators, it also affects both transcriptional activation and repression roles in a context-dependent manner. The detailed mechanisms of how 5-hmC regulates other genes altered by Tet in BMMSCs may need further investigation.66,67

In conclusion, depletion of Tet1 and Tet2 results in BMMSC impairment and an osteopenia phenotype. An increase in exosome secretion and reduction of intracellular accumulation of miR-297a-5p, miR-297b-5p, and miR-297c-5p, achieved by restoring the level of P2rX7 in Tet DKO BMMSCs, can rescue BMSC function and bone homeostasis.

Methods

Animals. Female C57BL/6J (JAX #000664), B6.129S4-Tet1tm1ste/J (JAX #017358, Tet1flox−/flox−), B6.129S-Tet2tm1ste/J (JAX #017573, Tet2flox−/flox−), and B6.Cg-Tg(Prlx1-cre)IC(1)J (JAX #005584, Prlx1cfx1 mice were purchased from the Jackson Laboratory (Bar Harbor, ME, USA). Age-matched littermates were used in all experiments. The 8–10-week-old C57Bl/6 mice were ovariectomized (OVX)22, and sham-operated age-matched female mice served as controls. We purchased immuno-compromised nude mice (Beige nu/nu, XIDIII) from Harlan (Indianapolis, IN, USA). To generate Tet1flox−/flox−Prlx1cfx1 mice, we mated Tet1flox−/flox−Prlx1cfx1 mice with Tet1flox+/−Prlx1cfx1 females, and littermates whose genetic status was Prlx1cfx1 were used as controls. All animal experiments were performed under institutional approved protocols for the use of animal research (University of Pennsylvania Institutional Animal Care and Use Committee #850478).

Antibodies. The antibodies to Tet1 (ab191698), Tet2 (ab94580), P2rX7 (ab88871), CD146 (ab25477), PDGFRα (ab65258), and OCN (ab10911) were purchased from Abcam (Cambridge, MA, USA). Antibodies to ALP (sc-28904), CD9 (sc-9148), and CD81 (sc-9158) were purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA). Antibody to Runx2 (8466) was obtained from Cell Signaling Technology (Danvers, MA, USA). Antibody to Tet3 (20602) was purchased from Novus Biologicals (Littleton, CO, USA). Anti-CD34-PE (551387) and SCA1-PE (553108) antibodies were purchased from BD Biosciences (San Jose, CA, USA). Anti-β-Actin antibody was purchased from Sigma-Aldrich (St. Louis, MO, USA).

Isolation of mouse BMMSCs. We collected femurs and tibias from mice and flushed out the bone marrow cells with 2% fetal bovine serum (FBS; Equitech-Bio, Kerrville, NY, USA) in phosphate-buffered saline (PBS). All nuclear cells (ANCs) were seeded (15 × 10^5 cells per dish) in 100 mm culture dishes (Corning, Tewksbury, MA, USA) and incubated at 37 °C under 5% CO2 conditions. After 48 h, non-adherent cells were washed by PBS and adherent cells were cultured in alpha minimum essential medium (a-MEM, Invitrogen, Grand Island, NY, USA) supplemented with 20% FBS, 2 mM l-glutamine (Invitrogen), 55 μM 2-mercaptoethanol (Invitrogen), 100 μg ml−1 streptomycin, and 100 U ml−1 penicillin (Invitrogen) for an additional 14 days. Mouse BMMSCs in passage one were used in this study. For CFU-F assay, we seeded 1 × 10^5 ANCs in 60 mm cell culture dishes (Corning). The cells were washed with PBS and stained with 1% toluidine blue solution with 2% pafamorphamide (PFA, Sigma-Aldrich) after 16 days of culturing. Clusters with more than 50 cells were counted as colonies under microscopy.

Isolation and culture of human BMSCs. We purchased human bone marrow from AllCells LLC (Alameda, CA, USA), which were aspirated from healthy human adult volunteers (20–35 years of age). The dissociated cell suspension was filtered through a 70 μm cell strainer, then cultured with a-MEM containing 10% FBS, 10 mM L-ascorbic acid phosphate, 100 U ml−1 penicillin, 100 μg ml−1 streptomycin, and 2 mM l-glutamine, incubated at 37 °C under 5% CO2 conditions. After 48 h, the non-adherent cells were removed. The adherent cells were passaged with 0.05% trypsin containing 1 mM EDTA after being cultured for 14 days.

Immunofluorescent staining. We seeded BMMSCs on chamber slides (Nunc, Rochester, NY, USA) (2 × 10^5/well) and fixed the cells with 4% PFA. The chamber slides or histological sections were incubated with primary antibodies (1:100) at 4 °C overnight, then treated with Alexa Fluor 488 or Alexa Fluor 568 conjugated secondary antibody (Santa Cruz Biotechnology; 1:200, Invitrogen) for 1 h at room temperature. Finally, we mounted the slides with Vectashield mounting medium containing 4',6-diamidino-2-phenyldale (DAPI, Vector Laboratories, Burlingame, CA, USA).

Western blotting. Total protein was lysed in M-Per mammalian protein extraction reagent (Thermo, Rockford, IL, USA). After the proteins (20 μg) were loaded and separated to 4–12% NuPAGE gel (Invitrogen), they were transferred to 12% NuPage gel containing 0.2 μm nitrocellulose membranes (Millipore, Billerica, MA, USA). Then, 0.1% Tween-20 and 5% non-fat dry milk were provided to block the membranes for 1 h, followed by overnight incubation with primary antibodies (1:1000) diluted in blocking solution. The membranes were washed and incubated for 1 h in horse-radish peroxidase (HRP)-conjugated secondary antibody (Santa Cruz Biotechnology; 1:10,000). SuperSignal West Pico Chemiluminescent Substrate (Thermo) and BioMax film (Kodak) were used to detect the immunoreactive proteins. All full blots presented in the main figures are displayed in the Supplementary Information.

Real-time PCR. We used miNeasy Mini Kit (Qiagen, Valencia, CA, USA) to isolate total RNA from the cultured cells according to the manufacturer’s instructions. For qPCR of miRNA, we used SuperScript III Reverse Transcriptase (RT) kit (Invitrogen) to prepare the complementary DNA (cDNA). qPCR was performed using SYBR Green Supermix (Bio-Rad, Hercules, CA, USA) and gene-specific primers. The level of miRNA expression for each gene was normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH). For qPCR of mRNA, miScript II RT Kit (Qiagen) was used to synthesize the cDNA. miScript SYBR Green PCR Kit (Qiagen) was used to perform real-time PCR. We used RNU6 as an endogenous control for BMSCs. A CFX96 Real-Time PCR System (Bio-Rad) was used for qPCR analysis.

RNA-sequencing. RNA-seq analyses of total RNA from vehicle and Tet1 and Tet2 siRNA-treated BMMSCs were performed at the Department of Biotechnology, Beijing Institute of Radiation Medicine. Three RNA samples from each group were used for RNA-seq analysis. For each sample, we used NEBNext Ultra RNA library
Pre Kit to prepare a sequencing library from 1 μg of total RNA, and 2 × 100 paired-end sequencing in fast run mode was performed using the HiSeq 2500 and Illumina TruSeq SBS Kit v2 (200 cycles).

Bioinformatics analysis. Illumina’s bcl bcl2fastq v1.8.4 software (Illumina,San Diego, CA) was used to convert the resulting base calling (bcl) to FASTQ files. Mapping RNA-seq reads on the mouse genome (Mus musculus GRCh38) after trimming the adapters, transcript assembly, and abundance estimation were performed using DNASTAR Lasergene v15.0 (DNASTAR, Madison, WI) and reported using FPKM (fragments per kilobase of exon per million fragments mapped). The Gene Pattern and Westatseal were used for functional analysis.

In vitro osteogenic differentiation. BMMSCs were cultured in osteogenic medium containing 100 μM 1-sarcosin acid 2-phosphate (Wako), 2 mM β-glycerophosphate (Sigma-Aldrich), and 10 nM dexamethasone (Sigma-Aldrich) in the growth medium. After 14 days of osteogenic induction, western blotting was performed to detect the expression levels of Runx2, ALP, and OCN. After 4 weeks of induction, mineralized nodule formation was detected by staining with 1% Alizarin Red S (Sigma-Aldrich) for the cultures. The stained positive areas were quantified using the National Institutes of Health (NIH) ImageJ software and shown as a percentage of the total area.

Cell proliferation assay. Mouse BMMSCs (10 × 10^6/well) were cultured on 2-well chamber slides (Nunc, Rochester, NY, USA) for 2–3 days. After being incubated with BrDU solution (1:100) (Invitrogen) for 20 h, the cultures were stained with BrDU antibody (1:200, Invitrogen) at 4 °C overnight, then treated with AlexaFluro 568 conjugated secondary antibody for 1 h at room temperature. Finally, Vectashield mounting medium containing DAPI (Vector Laboratories, Burlingame, CA, USA) was used to mounted slides. BrDU-positive cells were counted and indicated as a percentage of the total cell number, and 10 images were analyzed per subject. Three independent samples were repeated for each experimental group.

Isolation and characterization of exosomes. Exosomes were isolated from BMMSCs by ultracentrifuge. Exosome-depleted medium (complete medium depleted of FBS-derived exosomes by overnight centrifugation at 100,000 × g) was used to culture cells for 48 h. We used differential centrifugation to extract exosomes from culture supernatants of 12 × 10^6 BMMSCs, at 300,000 × g for 10 min, 3000 × g for 10 min, 20,000 × g for 30 min, and 120,000 × g for 70 min. For analysis of exosome protein secretion, Bradford assay (Bio-Rad Laboratories) was used to measure the amount of total protein in purified exosomes from 12 × 10^6 BMMSCs. Total exosome protein was normalized to 1×10^6 cells to show the amount of exosome protein secretion.

siRNA knockdown. CRISPR activation plasmid, Tet plasmid microRNA mimic, and inhibitor transfection. For siRNA knockdown, we seeded 0.2 × 10^6 BMMSCs on a 6-well culture plate. Tet1, Tet2, and P2rX7 siRNAs (Santa Cruz Biotechnology) were used to treat the BMMSCs according to the manufacturer’s instructions. Non-targeting control siRNAs (Santa Cruz Biotechnology) were used as negative controls. pcD3-fl-miR-Tet1 (Addgene #18052), pcD3-fl-miR-Tet2 (Addgene #69083), and pcD3-fl-miR-P2rX7 (Addgene #79611) were purchased from Addgene (Cambridge, MA). For P2rX7 CRISPR activation and Tet plasmid (Santa Cruz Biotechnology) transfection, we seeded 0.2 × 10^6 BMMSCs on a 6-well culture plate, and transfected with P2rX7 CRISPR activation plasmid (Santa Cruz Biotechnology) using Lipofectamine LTX with Plus reagent (Life Technologies) according to the manufacturer’s instructions. We used control CRISPR plasmids as a negative control. The miR-297a-5p, miR-297b-5p, and miR-297c-5p mimics, and inhibitors (Quagen) were transfected into cells according to the manufacturer’s instructions. Briefly, BMMSCs (0.2 × 10^6) were seeded on a 6-well culture plate and transfected with miR-297a-5p, miR-297b-5p, and miR-297c-5p mimics, or inhibitors using Lipofectamine LTX with Plus reagent (Life Technologies) according to the manufacturer’s instructions.

Methylation and hydroxymethylated DNA immunoprecipitation (mHIDIP). Immunoprecipitation of 5-mC and 5-hmC was performed using Active motif MeDIP kit and mHIDIP Kit with minor modifications. We used Branson sonicator to sonicate DNA into short fragments (100 to 1000 base pairs (bp)) for 20 min with 15 s on, 15 s off cycles at low power. We heat-denatured sonicated DNA at 95 °C for 10 min. Sonicated DNA (1 μg) was immunoprecipitated with 4 μl of mouse anti-5-methylcytosine or anti-5-hydroxymethylcytosine monoclonal antibody (Active Motif, 1 μg/ml). After overnight incubation at 4 °C, we added magnetic beads to the DNA-antibody mixture and samples were incubated for 2 h at 4 °C. Isolation of immunoprecipitated DNA was performed according to the kit instructions. SYBR® Green Supermix (Bio-Rad) was used to perform qPCR on a Bio-Rad CFX96 Real Time system, as indicated by the manufacturer’s protocol.

The percentage of enrichment was calculated relative to the amount of DNA used in the IP reaction.

Chromatin immunoprecipitation-quantitative PCR (ChIP-qPCR). 5×10^6 cells were cross-linked and used for each immunoprecipitation, and chromatin was sheared with a Branson sonicator. Millipore CHIP kit was used to perform immunoprecipitation according to the manufacturer’s protocol. To precipitate DNA-protein complexes, Tet1 and Tet2 antibodies were used and IgG was used as an isotype control. Percentage input was determined by removing an aliquot of the chromatin prior to immunoprecipitation and correcting the amplification of this DNA to amplification of the precipitated chromatin. Putative Tet1 and Tet2 binding sites in the P2rX7 promoter were investigated using MethPrimer software to predict the CpG island.

Transmission electron microscopy. For transmission electron microscopy (TEM), control and Tet DKO BMMSCs were collected by centrifugation and fixed with 2.5% glutaraldehyde overnight and then fixed with 1% osmium tetroxide for 2 h, dehydrated in a graded series of ethanol concentrations, and embedded in SPIPONB12 resin and polymerized. The block was sectioned by microtome (Leica EM UC6). The ultrathin sections approximately 70 nm, mounted on copper grids, uranyl acetate, and lead citrate were used to stain, and examined, and photographed with a FEI Tecnai spirit TEM (FEI Tecnai Spirit 120 kv).

Histology. To assess trabecular bone and bone marrow areas, femurs were fixed in 4% PFA, decalcified with 5% EDTA (pH 7.4), and embedded in paraffin. For histological analysis, sections were deparaffinized and stained with hematoxylin and eosin (H&E). The trabecular bone area percentage was then calculated using NIH ImageJ software.

Micro-Ct analysis. Femurs were fixed in 4% PFA, and analyzed using a µCT scanner (Scanco Medical CT 35, Scanco Medical AG, Bruttisellen, Switzerland). Briefly, the distal end of the femur corresponding to a 0 to 4.1 mm region above the growth plate was scanned at 6 μm isotropic voxel size. For the trabecular bone analysis, the images of the secondary spongiosa regions 0.6 to 1.8 mm above the highest point of the growth plate were contoured. BMD and BV/TV were calculated using standard 3D microstructural analysis. After smoothing the image with a 3D gaussian low-pass filter (Sigma 0.7 voxel), the CT images were segmented into bone and marrow regions by applying a visually chosen for the cortical bone assessment. The outer and inner perimeter of the cortical midshaft was determined by a 3D triangulation of the bone surface of the 20 slices, and the formula Ct.Th = 1/2 × BS/ BV was used to calculate cortical thickness. Ct.Ar = thickness of ring × length of middle line = thickness × (outer circumference + inner circumference)/2.

P2rX7 AAV treatment in Tet DKO mice. P2rX7 overexpression adeno-associated virus (P2rX7 AAV, Applied Biological Materials Inc., Richmond, BC, Canada) was overexpressed in vivo. P2rX7 AAV (1×10^9 GC) or AAV control virus (P2rX7 AAV, Applied Biological Materials Inc., Richmond, BC, Canada) was injected into the Tet DKO mice once a week for 4 weeks. After the therapy, samples were harvested immediately for histological and BMMSC isolation.

In vivo BMMSC-mediated bone formation. We subsequently implanted 4.0×10^6 BMMSCs mixed with 40 mg HA/TCP ceramic powder (Zimmer Inc., Warsaw, IN, USA) under the dorsal surface of 8-week-old immunocompromised mice. The transplants were harvested at 8 weeks post implantation, fixed in 4% PFA, and decalcified with 5% EDTA, then embedded in paraffin. The sections were stained with H&E. For quantification of in vivo new bone regeneration, we calculated the area of bone formation with 10 representative images from different regions of the BMMSC implants using ImageJ software (National Institutes of Health, Bethesda, MD). Each experimental group was repeated with three independent implants.

Dot blot assay. DNA was diluted to 100 ng/ml and a dilution series was performed. 1 μl was spotted on a 0.45 μm pore size positively charged nylon membrane and wait for drying in the air, then the membrane was baked in 80 °C vacuum oven for 2 h. The membrane was blocked with 5% milk/0.1% Tween-20/ Tris-buffered saline for 1 h, and being incubated with 5-hmC (1:1000) or 5-mC (1:1000) antibodies overnight at 4 °C. Then, the membrane was washed and incubated for 1 h in HRP-conjugated secondary antibody (Santa Cruz Biotechnology; 1:10,000). Finally, SuperSignal West Pico Chemiluminescent Substrate (Thermo) and BioMax film (Kodak) were used to do the detection.

Methylation-specific PCR and OxBS sequencing. To assess P2rX7 methylation status, optimized oxidative bisulfite sequencing (OxBS sequencing) was used. A highly selective chemical oxidizes 5-hmC to 5-formylcytosine (5fC) and then bisulfite converts the formylated 5fC to uracil, and appears as thymine (T) in sequencing analysis. The 5-mC is not deaminated and appears as a cytosine (C) in sequencing analysis. Oxidative bisulfite conversion, which is able to
produce an accurate readout distinguishing 5-mC from 5-hmC, was performed using a TrueMethyl™ kit (Cambridge Epigenetics, UK), according to the manufacturer’s instructions. For methylated-specific PCR, pretreated DNA was amplified with methylation-specific primers for P2rX7 as listed in the supplementary table 2 and were sequencing as we previously reported47.

Statistics and reproducibility. For animal study, we used at least five mice and experiments were performed three times, unless otherwise stated in the figure legends. No specific statistical test was used to determine the sample size. Comparisons between two groups were analyzed using independent unpaired two-tailed Student’s t-tests, and comparisons between more than two groups were analyzed using one-way analysis of variance with the Bonferroni correction if the data did not meet the normality distribution assumption. The p values of less than 0.05 were considered statistically significant. In vitro and in vivo experiments were studied in a non-blinded fashion, no method of randomization was used, and typically no sample was excluded for the analysis.

Data availability. The data that support the findings in this study are available from the corresponding author upon reasonable request. DNA-sequencing data have been deposited in the Gene Expression Omnibus (GEO) database by GSE108872.

Received: 6 July 2017 Accepted: 2 May 2018
Published online: 01 June 2018

References

1. Ito, S. et al. Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification. Nature 466, 1129–1133 (2010).

2. Tahiliani, M. et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 324, 930–935 (2009).

3. He, Y. F. et al. Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. Science 333, 1303–1307 (2011).

4. Ito, S. et al. Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylic acid. Science 333, 1300–1303 (2011).

5. Kob, K. P. et al. Tet1 and Tet2 regulate 5-hydroxymethylcytosine production and cell lineage specification in mouse embryonic stem cells. Cell Stem Cell 8, 200–213 (2011).

6. Song, C. X. et al. Selective chemical labeling reveals the genome-wide distribution of 5-hydroxymethylcytosine. Nat. Biotechnol. 29, 68–72 (2011).

7. Liu, R. et al. Ten-eleven translocation-2 (TET2) is a master regulator of smooth muscle cell plasticity. Circulation 128, 2047–2057 (2013).

8. Williams, K. et al. TET1 and hydroxymethylcytosine in transcription and DNA methylation fidelity. Nature 473, 343–348 (2011).

9. Cimmino, L., Abdel-Wahab, O., Levine, R. L. & Aifantis, I. TET family proteins and their role in stem cell differentiation and transformation. Cell Stem Cell 9, 193–204 (2011).

10. Ko, M., An, J. & Rao, A. DNA methylation and hydroxymethylation in hematologic differentiation and transformation. Curr. Opin. Cell Biol. 37, 60–73 (2015).

11. Ko, M. et al. TET proteins and 5-methylcytosine oxidation in hematological cancers. Immunol. Rev. 263, 6–21 (2015).

12. Rudenko, A. et al. Tet1 is critical for neuronal activity-regulated gene expression and memory extinction. Neuron 79, 1109–1112 (2013).

13. Taylor, S. E. et al. Stable 5-hydroxymethylcytosine (5hmC) acquisition marks promoter activation during chorionic differentiation. J. Bone Miner. Res. 31, 524–534 (2016).

14. Dawlaty, M. M. et al. Tet1 hydroxylase in mouse embryonic stem cells. J. Cell. Biochem. 112, 472–479 (2013).

15. Yang, L. et al. miR-93/Sp7 function loop mediates osteoblast mineralization. J. Bone Miner. Res. 27, 1598–1606 (2012).

16. Huang, J., Zhao, L., Xing, L. & Chen, D. MicroRNA-204 regulates Runx2 protein expression and mesenchymal progenitor cell differentiation. Stem Cells 28, 357–364 (2010).

17. Zhang, Y. et al. A program of miRNAs controls osteogenic lineage progression by targeting transcription factor Runx2. Proc. Natl. Acad. Sci. USA 108, 9863–9868 (2011).

18. Lai, R. et al. MSC secretes at least 3 EV types each with a unique permutation of membrane lipid, protein and RNA. J. Extracell. Vesicles 5, 8928 (2016).

19. Zhou, Y. et al. Exosomes transfer among different species cells and mediating miRNAs delivery. J. Cell. Biochem. 118, 4267–4274 (2017).

20. Skog, J. et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat. Cell Biol. 10, 1470–1476 (2008).

21. Wittwer, K. W. et al. Standardization of sample collection, isolation and analysis methods in extracellular vesicle research. J. Extracell. Vesicles 2, https://doi.org/10.3402/jev.v2i0.20360 (2013).

22. Qu, Y., Franchi, L., Nunez, G. & Dubyak, G. R. Nonclassical IL-1beta secretion stimulated by P2X7 receptors is dependent on inflammasome activation and correlated with exosome release in murine macrophages. J. Immunol. 179, 1913–1925 (2007).

23. Qu, Y. et al. P2X7 receptor-stimulated secretion of MHC class II-extracellular exosomes requires the ASC/NLRP3 inflammasome but is independent of caspase-1. J. Immunol. 182, 5052–5062 (2009).

24. Dubyak, G. R. P2X7 receptor regulation of non-classical secretion from immune effector cells. Cell Microbiol. 14, 1697–1706 (2012).

25. Moran-Crusio, K. et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell. 20, 11–24 (2011).

26. Ko, M. et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 468, 839–843 (2010).

27. Mahara, L. G. et al. JGF2P1 expression in human mesenchymal stem cells significantly affects their proliferation and is under the epigenetic control of TET1/2 demethylases. Stem Cells Dev. 23, 2501–2512 (2014).

28. Canalis, E. The fate of circulating osteoblasts. N. Engl. J. Med. 352, 2014–2016 (2010).

29. Crane, J. L. & Cao, X. Function of matrix IGF-1 in coupling bone resorption and formation. J. Med. (Beth.) 92, 107–115 (2014).

30. Zhang, P. et al. Histone H3K9 acetyltransferase PCAF is essential for osteogenic differentiation through bone morphogenetic protein signaling and may be involved in osteoprosis. Stem Cells 34, 2332–2341 (2016).

31. Chen, C. et al. mTOR inhibition rescues osteopenia in mice with systemic sclerosis. J. Exp. Med. 212, 73–91 (2015).

32. Liu, Y. et al. Hydrogen sulfide mediates mesenchymal stem cell function and bone homeostasis via regulation of Ca channel sulfhydration. Cell Stem Cell 15, 66–78 (2014).

33. Yang, R. et al. Hydrogen sulfide promotes Tet1- and Tet2-mediated Foxp3 demethylation to drive regulatory T cell differentiation and maintain immune homeostasis. Immunity 43, 251–263 (2015).

34. Dethoumaux, F. et al. Mutation in TET2 in myeloid cancers. N. Engl. J. Med. 360, 2289–2301 (2009).
49. Wang, L. et al. IFN-gamma and TNF-alpha synergistically induce mesenchymal stem cell impairment and tumorigenesis via NFkappaB signaling. Stem Cells 31, 1383–1395 (2013).

50. Raposo, G. & Stoorvogel, W. Extracellular vesicles: exosomes, microvesicles, and friends. J. Cell. Biol. 200, 373–383 (2013).

51. Valadi, H. et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat. Cell Biol. 9, 654–659 (2007).

52. Robbins, P. D. & Morelli, A. E. Regulation of immune responses by extracellular vesicles. Nat. Rev. Immunol. 14, 195–208 (2014).

53. Gomes, C., Keller, S., Altevogt, P. & Costa, J. Evidence for secretion of Cu/Zn superoxide dismutase via exosomes from a cell model of amyotrophic lateral sclerosis. Neurosci. Lett. 428, 43–46 (2007).

54. Wolff, K., Gatti, S., Wettstein, J. G. & Foster, R. G. Sleep and circadian rhythm disruption in psychiatric and neurodegenerative disease. Nat. Rev. Neurosci. 11, 589–599 (2010).

55. Colombo, M., Raposo, G. & Thery, C. Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu. Rev. Cell Dev. Biol. 25, 275–309 (2009).

56. Qu, Y. & Dubyk, G. R. P2X7 receptors regulate multiple types of membrane trafficking responses and non-classical secretion pathways. Purinergic Signal. 5, 163–173 (2009).

57. Ke, H. Z. et al. Deletion of the P2X7 nucleotide receptor reveals its regulatory roles in bone formation and resorption. Mol. Endocrinol. 17, 1356–1367 (2003).

58. Lenertz, L. Y., Baughman, C. J., Waldschmidt, N. V., Thaler, R. & van Wijnen, A. J. Control of bone development by P2X and P2Y receptors expressed in mesenchymal and hematopoietic cells. Gene 570, 1–7 (2015).

59. Bartel, D. P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116, 281–297 (2004).

60. Zhou, P., Huang, B., Xu, X. & Sessa, W. C. Ten-eleven translocation (Tet) and thymine DNA glycosylase (TDG), components of the demethylation pathway, are direct targets of miRNA-29a. Biochem. Biophys. Res. Commun. 437, 368–373 (2013).

61. Fu, X. et al. MicroRNA-26a targets ten eleven translocation enzymes and is regulated during pancreatic cell differentiation. Proc. Natl. Acad. Sci. USA 110, 17892–17897 (2013).

62. Loriot, A. et al. A novel cancer-germline transcript carrying pro-metastatic miR-105 and TET-targeting miR-767 induced by DNA hypomethylation in tumors. Epigenetics 9, 1163–1171 (2014).

63. Song, S. J., et al. MicroRNA-antagonism regulates breast cancer stemness and metastasis via TET-family dependent chromatin remodeling. Cell 154, 311–324 (2013).

64. Pratap, J. et al. Cell growth regulatory role of Runx2 during proliferative expansion of preosteoblasts. Cancer Res. 63, 5357–5362 (2003).

65. An, J., Rao, A. & Ko, M. TET family dioxygenases and DNA demethylation in stem cells and cancers. Exp. Mol. Med. 49, e323 (2017).

66. Wu, H. et al. Dual functions of Tet1 in transcriptional regulation in mouse embryonic stem cells. Nature 473, 389–393 (2011).

67. Mellen, M., Ayata, P., Dewell, S., Kriaucionis, S. & Heintz, N. MeCP2 binds to 5hmC enriched within active genes and accessible chromatin in the nervous system. Cell 151, 1417–1430 (2012).

68. Thery, C., Amigorena, S., Raposo, G. & Clayton, A. Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr. Protoc. Cell Biol. 3, 3.22.1-3.22.29 (2006).

69. Li, L. C. & Daihya, R. MethPrimer: designing primers for methylation PCRs. Bioinformatics 18, 1427–1431 (2002).

70. Booth, M. J. et al. Oxidative bisulfite sequencing of 5-methylcytosine and 5-hydroxymethylcytosine. Nat. Protoc. 8, 1841–1851 (2013).

Acknowledgements

This work was supported by grants from the National Institute of Dental and Craniofacial Research, National Institutes of Health, Department of Health and Human Services (R01DE017469 to S.S. and K99DE025915 to C.C.), International Science & Technology Cooperation Program of China (2015DFB3004 to S.S. and Y.Z.), an NIH NIAMS fellowship (T32AR007442), the Young Elite Scientist Sponsorship Program by CAST (2017QNRC001), Beijing Natural Science Foundation (7182182), and an Schoenleber Pilot Research Grant from University of Pennsylvania School of Dental Medicine. We would like to thank the Center for Biological Imaging, the Institute of Biophysics, for our electron microscopy work and we would be grateful to Lei Sun and Can Peng for their help of making EM samples and taking EM images. We would like to thank the Department of Biotechnology, Beijing Institute of Radiation Medicine, for our RNA-sequencing work and we would be grateful to Zhe Zhou for his help for doing RNA-sequencing and bioinformatics analysis.

Author contributions

S.S. and Y.Z. conceived the project. S.S., R.Y., T.Y., and Y.Z. designed the experiments. R. Y., T.Y., C.C., X.G., X.K., and D.L. performed the experiments and analyzed the data. S.S. and T.Y. wrote the manuscript.

Additional information

Supplementary Information accompanies this paper at https://doi.org/10.1038/s41467-018-04464-6.

Competing interests: The authors declare no competing interests.

Reprints and permission information is available online at http://npg.nature.com/reprintsandpermissions/

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s) 2018